The Filing Desk

Ginkgo Bioworks vs Mesa Laboratories

Ginkgo Bioworks DNA · Mesa Laboratories MLAB · Life Sciences Tools & Services

Mesa Laboratories reported revenue of $249 million in fiscal 2026, 1.5 times Ginkgo Bioworks' $170 million in fiscal 2025. Ginkgo Bioworks' revenue fell 25.1% in its latest year, and Mesa Laboratories' grew 3.4%. Ginkgo Bioworks had an operating margin of -185.3%, against 7.4% at Mesa Laboratories. Free cash flow was −$179 million at Ginkgo Bioworks and $40 million at Mesa Laboratories. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.

Side by side

Ginkgo BioworksMesa Laboratories
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Mar 31, 2026
Revenue$170M$249M
Revenue growth−25.1%3.4%
Revenue growth a year, last 5 years17.3%13.2%
Gross margin—63.5%
Operating margin−185.3%7.4%
Net margin−183.8%2.7%
Free cash flow−$179M$40M
Free cash flow margin−105.0%15.9%
Return on capital—4.8%
Net debt to EBITDA—1.0x
Dividends and buybacks$0M$4M
Change in diluted share count6.9%2.7%
Last close$9.61$139.01
P/E at the last close—120.9×
Insider trades, last 12 months——
Piotroski F-score—8 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Ginkgo BioworksMesa Laboratories
Operating margin
Percent of revenue
Ginkgo BioworksMesa Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ginkgo BioworksMesa Laboratories

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ginkgo Bioworks and Mesa Laboratories pages.